Data compiled by Redley Lamar · ChainSifter Intelligence
7Suppliers
4Customers
2Debt Items
0Related Chains
Source-Backed Evidence Depth
Liminatus Pharma, Inc. (LIMN) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
14Total relationships
5Distinct source URLs
10High confidence
0.814Average confidence
2026-07-01Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Liminatus Pharma, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CLEAR-STREET-LLC
CLEAR-STREET-LLC
92%
the Company agreed to issue 4,000,000 shares of its common stock, par value $0.0001 per share ('Common Stock'), to the Holder in exchange for the surrender and cancellation of 805,377 warrants to pur…
INNOBATION-BIO-CO-LTD
INNOBATION-BIO-CO-LTD
92%
Research and development expenses consist of costs incurred by InnoBation Bio Co, Ltd. ("Innobation") who was performing the research and development activities for the Company in accordance with the…
MAXIM-GROUP-LLC
MAXIM-GROUP-LLC
92%
In connection with the transaction described above, the Company entered into a financial advisory services agreement, dated June 3, 2026, with Maxim Group LLC ("Maxim"), pursuant to which the Company…
CURIS-BIOTECH-HOLDINGS-LLC
CURIS-BIOTECH-HOLDINGS-LLC
90%
the Company received an exclusive license to develop and commercialize products... from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company
INNOCSAI
INNOCSAI
90%
the aggregate consideration to be paid to existing members of InnocsAI is 1,600,000,000 shares of the Company's common stock
VALETUDO
VALETUDO
85%
the Company received an exclusive license to develop and commercialize products... from Curis Biotech Holdings LLC, the parent company of Valetudo, a related party of the Company
VALETUDO-THERAPEUTICS-LLC
VALETUDO-THERAPEUTICS-LLC
80%
Valetudo Therapeutics LLC is a member of InnocsAI
Liminatus Pharma, Inc. Customers
Ticker
Name
Confidence
Evidence
CURIS-BIOTECH-HOLDINGS-LLC
CURIS-BIOTECH-HOLDINGS-LLC
62%
authoritative guidance in ASC 480, Distinguishing liabilities from equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding…
FEELUX-CO-LTD
FEELUX-CO-LTD
62%
authoritative guidance in ASC 480, Distinguishing liabilities from equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding…
INNOBATION-BIO-CO-LTD
INNOBATION-BIO-CO-LTD
62%
authoritative guidance in ASC 480, Distinguishing liabilities from equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding…
MAXIM-GROUP-LLC
MAXIM-GROUP-LLC
62%
public warrants as of December 31, 2025 and 2024. The Company further considered specific unobservable inputs, such as the probability and timing of events and the expected equity value of the underl…
Liminatus Pharma, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
LIMN-DEBT-10713
Warrants outstanding: 1
90%
xbrl warrant detail from xbrl 2026-03-31.
LIMN-DEBT
Debt stack $1.4M
90%
Market cache reports total debt of $1.4M.
Liminatus Pharma, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Liminatus Pharma, Inc..
Liminatus Pharma, Inc. Ownership
Holder
Name
Confidence
Evidence
LIMN-OWNER-CITADEL-ADVISORS-LLC
CITADEL ADVISORS LLC
90%
13F overlay lists CITADEL ADVISORS LLC as top holder; 15 tracked holders.
Liminatus Pharma, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
